In another retrospective study, 63 patients, mostly with high-risk prostate cancer (40/63, 64%), received PSMA-targeted PET/CT for rising PSA that did not meet the Phoenix Criteria after primary conventional or moderately hypofractionated EBRT (37). Here, FOLH1 is linked to prostate carcinoma.